CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Miravant Medical Technologies is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Miravant Medical Technologies
336 Bollay Drive
Phone: (805) 685-9880p:805 685-9880 SANTA BARBARA, CA  93117  United States Ticker: MRVTMRVT
This company ceased filing statements with the SEC on 3/31/2006.
Business Summary
Miravant Medical Technologies is a pharmaceutical research and development company engaged in photodynamic therapy (PDT), a treatment modality based on drugs that respond to light. The drug and light procedures involve three components, the photoselective drugs, light producing devices and light delivery devices. The Company's products have been developed in-house and with outside collaborators and have been used in various clinical and preclinical investigations. Its most advanced drug, PHOTREX, generic name rostaporfin, has completed two Phase III clinical trials for the treatment of wet age-related macular degeneration (AMD). Miravant has branded its version of PDT technology with the trademark PhotoPoint.
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/200512/31/2004YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Chairman of the Board Robert J.Sutcliffe 60 7/8/2005 1/31/2005
Chief Financial Officer, Treasurer, Assistant Secretary John M.Philpott 55 1/1/1999 3/1/1995
President, Director David E.Mai 65 5/1/1996 3/1/1994
3 additional Officers and Directors records available in full report.

Business Names
Business Name
Miravant Cardiovascular, Inc.
Miravant Pharmaceuticals, Inc.
Miravant Systems, Inc.
MRVT

General Information
Number of Employees: 47 (As of 3/14/2005)
Outstanding Shares: 37,856,968 (As of 12/31/2018)
Shareholders: 6,000
Stock Exchange: OTC
Federal Tax Id: 770222872
Fax Number: (805) 685-7981
Email Address: mail@miravant.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, August 28, 2023